Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 10/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970355 | 0.93 | ADORA1 (0.83) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL8288691 | 0.88 | ADORA1 (0.68) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL16020430 | 0.85 | NPSR1 (0.55) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL10856142 | 0.85 | ADORA1 (0.72) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL13739529 | 0.84 | ADORA1 (0.78) | ADORA1MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL19475087 | 0.84 | ADORA1 (0.73) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL6997953 | 0.84 | ADORA1 (0.73) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL938054 | 0.84 | ADORA1 (1.00) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL10859421 | 0.84 | ADORA1 (0.69) | ADORA1MAPTKDM4EGAANPSR1 | |
| SCHEMBL16017714 | 0.83 | ADORA1 (0.57) | ADORA1MAPTKDM4EGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | VEGFA, EDF1, FLT1 | ADORA1 2273/4885MAPT 4404/4885KDM4E 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.